These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 25548993)

  • 41. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
    Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
    J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD30+ large cell transformation of mycosis fungoides after psoralen plus ultraviolet A photochemotherapy.
    Ogino J; Saga K; Kagaya M; Kamada A; Hirosaki K; Kaneko R; Jimbow K
    Br J Dermatol; 2007 Jan; 156(1):148-51. PubMed ID: 17199582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
    Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
    Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression--a disease of follicular helper T-cells?
    Kempf W; Kazakov DV; Cipolat C; Kutzner H; Roncador G; Tomasini D
    Am J Dermatopathol; 2012 Oct; 34(7):757-61. PubMed ID: 22722467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mycosis fungoides with spontaneously regressing CD30-positive tumorous lesions.
    Woodrow SL; Basarab T; Russell Jones R
    Clin Exp Dermatol; 1996 Sep; 21(5):370-3. PubMed ID: 9136160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
    Wong HK
    G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
    Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
    Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis.
    Assaf C; Hummel M; Zemlin M; Steinhoff M; Geilen CC; Stein H; Orfanos CE
    J Clin Pathol; 2004 Dec; 57(12):1325-8. PubMed ID: 15563677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
    An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr virus-negative Hodgkin's lymphoma after mycosis fungoides: molecular evidence for distinct clonal origin.
    Kremer M; Sandherr M; Geist B; Cabras AD; Höfler H; Fend F
    Mod Pathol; 2001 Feb; 14(2):91-7. PubMed ID: 11235910
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
    del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
    Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Folliculotropic mycosis fungoides (stage IIA) progressing to Sézary syndrome: a case report.
    Agar N; Whittaker SJ
    Br J Dermatol; 2008 Nov; 159(5):1197-9. PubMed ID: 18764843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
    Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
    JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.